Further, an attenuation of angiopoietin-like 3 activity, an inhibitor of lipoprotein lipase (LPL), may be involved in the amelioration of the metabolic syndrome-associated dyslipidemia (Figure 2). Here, ANGPTL3 is linked to metabolic syndrome.